Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31249024 | 1.00 | KDM4E (0.61) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL10372730 | 0.90 | KDM4E (0.51) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL32688151 | 0.89 | KDM4E (0.63) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL840080 | 0.89 | KDM4E (0.63) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL840079 | 0.88 | KDM4E (0.64) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| Hydrochloric Acid SCHEMBL3851196 | 0.88 | KDM4E (0.61) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL13057973 | 0.86 | KDM4E (0.62) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL10373208 | 0.85 | KDM4E (0.50) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL32688153 | 0.77 | KDM4E (0.54) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL10255758 | 0.76 | PARP1 (0.53) | KDM4EALDH1A1HSD17B10HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201206-A1 | METHODS FOR KILLING ANTIBIOTIC TOLERANT BACTERIA | THE PENN STATE RESEARCH FOUNDATION | 2023-06-29 | — | — | US | claimed |
| EP-1437122-B1 | Composition for dyeing keratinic fibers comprising diheteroarylmethane direct dye and dyeing process using this composition | OREAL (FR) | 2010-03-03 | — | — | EP | claimed |
| US-7217297-B2 | Composition for dyeing keratin fibers comprising a defined diheteroylarylmethane direct dye or a leuco precursor of this dye and dyeing method using it | L'OREAL S.A. (FR) | 2007-05-15 | — | — | US | claimed |
| US-20040187229-A1 | Composition for dyeing keratin fibers comprising a defined diheteroylarylmethane direct dye or a leuco precursor of this dye and dyeing method using it | L'OREAL S.A. (FR) | 2004-09-30 | — | — | US | claimed |
| EP-1437122-A1 | Composition for dyeing keratinic fibers comprising a diheteroarylmethane direct dye or its lecuco precursor and dyeing process using this composition | L'OREAL (FR) | 2004-07-14 | — | — | EP | claimed |
| EP-3080121-B1 | FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-09-04 | — | — | EP | disclosed |
| US-9932343-B2 | Fused tricyclic benzimidazoles derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-04-03 | — | — | US | disclosed |
| US-9932343-B2 | Fused tricyclic benzimidazoles derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-04-03 | — | — | US | disclosed |
| US-20160304523-A1 | Fused Tricyclic Benzimidazoles Derivatives As Modulators of TNF Activity | SANOFI (FR) | 2016-10-20 | — | — | US | disclosed |
| US-20160304523-A1 | Fused Tricyclic Benzimidazoles Derivatives As Modulators of TNF Activity | SANOFI (FR) | 2016-10-20 | — | — | US | disclosed |
| EP-3080121-A1 | FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080121-A1 | FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| US-20090042873-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-12 | — | — | US | disclosed |
| US-7217297-B2 | Composition for dyeing keratin fibers comprising a defined diheteroylarylmethane direct dye or a leuco precursor of this dye and dyeing method using it | L'OREAL S.A. (FR) | 2007-05-15 | — | — | US | disclosed |
| US-20040187229-A1 | Composition for dyeing keratin fibers comprising a defined diheteroylarylmethane direct dye or a leuco precursor of this dye and dyeing method using it | L'OREAL S.A. (FR) | 2004-09-30 | — | — | US | disclosed |
| EP-1437122-A1 | Composition for dyeing keratinic fibers comprising a diheteroarylmethane direct dye or its lecuco precursor and dyeing process using this composition | L'OREAL (FR) | 2004-07-14 | — | — | EP | disclosed |
| EP-0571253-B1 | Benzimidazole derivatives with antidiabetic and antiplatelet aggregation activity | ADIR (FR) | 1998-11-04 | — | — | EP | disclosed |
| US-5639756-A | ANTIDIABETIC AGENTS | ADIR ET COMPAGNIE (FR) | 1997-06-17 | — | — | US | disclosed |
| US-5623073-A | ANTIDIABETIC AGENT | ADIR ET COMPAGNIE (FR) | 1997-04-22 | — | — | US | disclosed |
| EP-0571253-A1 | Benzimidazole derivatives with antidiabetic and antiplatelet aggregation activity | ADIR ET COMPAGNIE (FR) | 1993-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304523-A1 | Fused Tricyclic Benzimidazoles Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | KDM4E 4047/4885ALDH1A1 205/4885HSD17B10 3973/4885 |
| US-20040187229-A1 | Composition for dyeing keratin fibers comprising a defined diheteroylarylmethane direct dye or a leuco precursor of this dye and dyeing method using it | KRT18, KMO, DLD | KDM4E 819/4885ALDH1A1 1560/4885HSD17B10 195/4885 |
| US-20090042873-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | CYP3A5, CYP2C8, PAICS | KDM4E 1797/4885ALDH1A1 484/4885HSD17B10 1941/4885 |
| US-20230201206-A1 | METHODS FOR KILLING ANTIBIOTIC TOLERANT BACTERIA | CLPP, SPOUT1, CASP3 | KDM4E 3031/4885ALDH1A1 942/4885HSD17B10 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.